Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 36,387 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 36,387 shares of the company’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $0.42, for a total transaction of $15,282.54. Following the completion of the transaction, the director owned 919,060 shares of the company’s stock, valued at $386,005.20. This represents a 3.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total transaction of $31,936.50.
• On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $39,341.25.
• On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.43, for a total transaction of $36,934.85.
• On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $28,336.50.
• On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.50, for a total transaction of $11,092.00.
• On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $43,446.40.
• On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total transaction of $22,745.16.
• On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.70, for a total transaction of $214,018.70.
• On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $49,824.18.
• On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.66, for a total transaction of $9,659.10.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ:HOWL opened at $0.46 on Wednesday. The company has a 50-day simple moving average of $0.77 and a 200-day simple moving average of $0.76. Werewolf Therapeutics, Inc. has a one year low of $0.40 and a one year high of $2.38. The stock has a market capitalization of $22.51 million, a price-to-earnings ratio of -0.37 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. As a group, research analysts forecast that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on HOWL shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Wall Street Zen cut shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Werewolf Therapeutics presently has an average rating of “Hold” and a consensus price target of $3.75.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in HOWL. Regal Investment Advisors LLC raised its holdings in Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. raised its holdings in Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares in the last quarter. Qube Research & Technologies Ltd purchased a new position in Werewolf Therapeutics during the second quarter worth about $48,000. AQR Capital Management LLC purchased a new position in Werewolf Therapeutics during the first quarter worth about $79,000. Finally, Bridgeway Capital Management LLC raised its holdings in Werewolf Therapeutics by 157.7% during the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares in the last quarter. 64.84% of the stock is owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.